The Relationship of Asthma Biologics to Remission for Asthma

[1]  H. Ortega,et al.  Assessment of the long‐term safety of mepolizumab and durability of clinical response in patients with severe eosinophilic asthma , 2019, The Journal of allergy and clinical immunology.

[2]  P. Woodruff,et al.  Measures of gene expression in sputum cells can identify TH2-high and TH2-low subtypes of asthma. , 2014, The Journal of allergy and clinical immunology.

[3]  Ian D Pavord,et al.  Mepolizumab treatment in patients with severe eosinophilic asthma. , 2014, The New England journal of medicine.

[4]  G. Yancopoulos,et al.  Targeting key proximal drivers of type 2 inflammation in disease , 2015, Nature Reviews Drug Discovery.

[5]  S. Holgate,et al.  Safety and tolerability of omalizumab , 2009, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[6]  E. Bleecker,et al.  Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial , 2016, The Lancet.

[7]  Bora study investigators.  Long-term safety and efficacy of benralizumab in patients with severe, uncontrolled asthma: 1-year results from the BORA phase 3 extension trial , 2019 .

[8]  Ian D Pavord,et al.  Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial , 2012, The Lancet.

[9]  P. Tugwell,et al.  American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. , 2011, Arthritis and rheumatism.

[10]  E. Bleecker,et al.  Predictors of enhanced response with benralizumab for patients with severe asthma: pooled analysis of the SIROCCO and CALIMA studies. , 2018, The Lancet. Respiratory medicine.

[11]  I. Pavord,et al.  An Expert Consensus Framework for Asthma Remission as a Treatment Goal. , 2019, The Journal of allergy and clinical immunology.

[12]  W. Busse,et al.  Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial , 2016, The Lancet.

[13]  E. Bel,et al.  Clinical predictors of remission and persistence of adult‐onset asthma , 2018, The Journal of allergy and clinical immunology.

[14]  I. Pavord,et al.  Dupilumab Efficacy and Safety in Moderate‐to‐Severe Uncontrolled Asthma , 2018, The New England journal of medicine.

[15]  S. Szefler.  Asthma across the lifespan: Time for a paradigm shift. , 2018, The Journal of allergy and clinical immunology.

[16]  K. Rabe,et al.  Efficacy and Safety of Dupilumab in Glucocorticoid‐Dependent Severe Asthma , 2018, The New England journal of medicine.

[17]  Philip Marcus,et al.  Development of the asthma control test: a survey for assessing asthma control. , 2004, The Journal of allergy and clinical immunology.

[18]  P. Gergen,et al.  Development and validation of the Composite Asthma Severity Index--an outcome measure for use in children and adolescents. , 2012, The Journal of allergy and clinical immunology.

[19]  Vernon M Chinchilli,et al.  Long-term inhaled corticosteroids in preschool children at high risk for asthma. , 2006, The New England journal of medicine.

[20]  D. Postma,et al.  Patterns of Growth and Decline in Lung Function in Persistent Childhood Asthma. , 2016, The New England journal of medicine.

[21]  P. Gergen,et al.  Development and Initial Validation of the Asthma Severity Scoring System (ASSESS). , 2020, The Journal of allergy and clinical immunology.

[22]  J. Fahy.  Type 2 inflammation in asthma — present in most, absent in many , 2014, Nature Reviews Immunology.

[23]  Eva Rönmark,et al.  Remission and Persistence of Asthma Followed From 7 to 19 Years of Age , 2013, Pediatrics.

[24]  W. Busse,et al.  Omalizumab Effectiveness by Biomarker Status in Patients with Asthma: Evidence From PROSPERO, A Prospective Real-World Study. , 2019, The journal of allergy and clinical immunology. In practice.

[25]  C. Sorkness,et al.  Development and cross-sectional validation of the Childhood Asthma Control Test. , 2007, The Journal of allergy and clinical immunology.